Genscript Biotech Corporation
https://www.genscript.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genscript Biotech Corporation
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
Tougher China Data Protection Laws Put Health Players On Alert
First LinkedIn, now Yahoo, the exodus of global tech giants from China indicates a toughening regulatory environment over personal data collection, storage and use with implications for pharma. Buckle up for a bumpy ride, experts say.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- CustomArray
- Legend Biotech USA Inc.
- Legend Biotech Ireland Limited
- Nanjing GenScript Co Ltd
- Nanjing Legend Biotechnology Co., Ltd.
- GenScript ProBio